Thelansis

  AL amyloidosis, also known as amyloid light chain amyloidosis, is a rare condition where a small B-cell clone, often a plasma cell clone, produces monoclonal light chains. These light chains can cause organ toxicity and deposit in tissues as amyloid fibrils. The clinical manifestations depend on the affected organs, but symptoms are often recognized late. Patients diagnosed at advanced stages, especially when heart involvement is present, face a high risk of death within a few months. Hematologists can screen individuals with known monoclonal gammopathy for amyloid organ dysfunction and damage, allowing for a presymptomatic diagnosis. Detectable monoclonal gammopathy and elevated biomarkers of organ involvement precede symptoms. Treatment aims to target the underlying clone and achieve early and profound hematologic and organ response long-term. Close monitoring of hematologic response is essential to identify nonresponders and shift them to rescue treatments. Autologous Stem C...